Read-Gene Overview
- Founded
- 2005

- Status
- Public
- Employees
- 24

- Stock Symbol
- RDG

- Share Price
- $0.95
- (As of Friday Closing)
Read-Gene General Information
Description
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
Contact Information
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
WAR
Primary Office
- Ul. Alabastrowa 8
- Grzepnica, 72-003
- Poland
+48 91 000 00 00
Read-Gene Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.95 | $0.83 | $0.22 - $1.12 | $11.2M | 5.51K | $0.05 |
Read-Gene Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 4,137 | 1,013 | 751 | 4,455 |
Revenue | 1,676 | 1,658 | 1,972 | 1,270 |
EBITDA | 599 | 427 | 668 | 53 |
Net Income | 593 | 31 | 224 | 14 |
Total Assets | 4,145 | 4,279 | 4,447 | 5,226 |
Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Read-Gene Signals
Growth Rate

0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile

-35.5%.
530%
Size Multiple

219x
Median
Size Multiple
219x, 100th %ile

0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial